Amgen, Inc. (NASDAQ:AMGN)
A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
herb1000
(< 20)
Submitted: 4/24/2007 8:36:28 PM :
Start Price:
$60.34
AMGN Score:
+20.53
Massive company that is superbly managed, Pipeline has enormous promise
Recs
THITLE
(< 20)
Submitted: 4/24/2007 5:54:41 PM :
Start Price:
$60.34
AMGN Score:
-20.53
NO MAJOR NEW DRUGS IN THE NEAR FUTURE.
Recs
onesided
(63.44)
Submitted: 4/24/2007 4:52:37 PM :
Start Price:
$60.34
AMGN Score:
+20.53
Drugs in the pipeline will start to flow.
Recs
harbst
(96.05)
Submitted: 4/24/2007 1:58:06 PM :
Start Price:
$59.76
AMGN Score:
+21.19
dominates fast growing market
Recs
HBearfool
(36.80)
Submitted: 4/23/2007 12:52:32 PM :
Start Price:
$61.53
AMGN Score:
+18.09
One of top biotech companies.
Recs
lpalencia
(< 20)
Submitted: 4/23/2007 1:06:54 AM :
Start Price:
$60.95
AMGN Score:
+19.17
60 is a fair price to pick it up for the long term.
Recs
jrbuff
(31.09)
Submitted: 4/22/2007 2:56:14 PM :
Start Price:
$60.95
AMGN Score:
+19.17
earnings speculation
Recs
DONTHEONE
(76.40)
Submitted: 4/22/2007 9:41:03 AM :
Start Price:
$60.95
AMGN Score:
+19.17
Solid research and well managed company. The true leader of biotech stocks.
Recs
PookieShadow
(78.44)
Submitted: 4/21/2007 2:09:38 PM :
Start Price:
$60.95
AMGN Score:
-19.17
Current sales are based principally on a single product that is facing tough competition - several other players with improved products that will take market share
Recs
bheald6
(42.15)
Submitted: 4/20/2007 10:24:24 AM :
Start Price:
$60.98
AMGN Score:
+18.98
This cinderella kid just wins baby
Recs
wfm1
(< 20)
Submitted: 4/19/2007 4:00:11 PM :
Start Price:
$61.35
AMGN Score:
-18.33
Development pipeline weakness and increased internal costs will make the next few months of this "heavy" bio weaker.
Recs
desertblossom
(< 20)
Submitted: 4/19/2007 3:20:53 PM :
Start Price:
$61.12
AMGN Score:
+18.04
It is unknown if any drug company will be able to produce generic versions of biotech drugs. I personally take Enbrel and it is the best RA treatment available.
Recs
hariyali
(53.56)
Submitted: 4/19/2007 1:51:37 PM :
Start Price:
$61.70
AMGN Score:
+17.11
Strong company and has been down offlate. Will recover
Recs
kkdman
(77.90)
Submitted: 4/18/2007 8:58:53 PM :
Start Price:
$62.07
AMGN Score:
+15.91
Too many pluses to be this low!
Recs
magicalthinking
(31.72)
Submitted: 4/18/2007 4:04:12 PM :
Start Price:
$62.07
AMGN Score:
+15.91
Great pipeline
Recs
teasdale100
(< 20)
Submitted: 4/18/2007 9:22:10 AM :
Start Price:
$58.66
AMGN Score:
+22.45
The bear case doesn't make sense. You have to stress the sales assumptions with outlandish value destruction to arrive at current price. Off-label prescribing is at risk for EPO franchise, and Roche is knocking on the door - but this downside scenario is more than baked in.
Recs
jphirsch
(31.88)
Submitted: 4/17/2007 10:36:55 PM :
Start Price:
$58.66
AMGN Score:
+22.45
AMGN's multiples are currently very low and it will recover.
Recs
sandersj
(< 20)
Submitted: 4/16/2007 5:39:43 AM :
Start Price:
$58.60
AMGN Score:
+22.07
Kroondossier
Recs
xdogg
(< 20)
Submitted: 4/13/2007 7:41:42 PM :
Start Price:
$58.60
AMGN Score:
+22.07
AMGN looks great in the long run, and its at a very nice price right now.
Recs
todd9
(69.43)
Submitted: 4/13/2007 4:31:42 PM :
Start Price:
$58.60
AMGN Score:
+22.07
Price is to low. Buy on the negative news.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 181 - 200 of 333 : « Previous 5 6 7 8 9 10 11 12 13 14 Next »